Tolmar, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$8.5M
Doctors Paid
9,082
Transactions
24,484
2024 Total
$2.5M
Payment Breakdown by Category
Research$7.8M (91.1%)
Food & Beverage$410,547 (4.8%)
Consulting$58,568 (0.7%)
Travel$13,078 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.8M | 2,872 | 91.1% |
| Food and Beverage | $410,547 | 20,366 | 4.8% |
| Honoraria | $241,518 | 115 | 2.8% |
| Consulting Fee | $58,568 | 24 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $25,500 | 3 | 0.3% |
| Travel and Lodging | $13,078 | 20 | 0.2% |
| Education | $7,637 | 1,084 | 0.1% |
Payments by Type
Research
$7.8M
2,872 transactions
General
$756,847
21,612 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| TOL3010B | $1.9M | 0 | 381 |
| TOL2506A | $1.6M | 5 | 662 |
| Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064%) in the treatment of Scalp Psoriasis | $1.4M | 0 | 241 |
| A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | $873,387 | 0 | 1,065 |
| A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO for 12 Months | $529,422 | 0 | 131 |
| Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study | $505,584 | 0 | 162 |
| TOL2581A | $170,193 | 3 | 31 |
| A Phase 3, Single Arm, OpenLabel Study Evaluating Ovarian Suppression Following ThreeMonth Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with HormoneReceptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)Negative Breast Cancer | $164,323 | 0 | 88 |
| TOL2707A | $150,335 | 0 | 5 |
| TOL2708C | $118,140 | 0 | 20 |
| A Pivotal Pharmacokinetic Bioequivalence Study Comparing Genericto Reference Liposome-Encapsulated Doxorubicin Hydrochloride inSubjects with Epithelial Ovarian Carcinoma Who Have FailedPlatinum-Based Chemotherapy | $115,045 | 0 | 14 |
| TOL2581A-CPP | $100,953 | 3 | 35 |
| TOL2506A-EXT | $67,270 | 0 | 25 |
| TOL2649G | $67,179 | 0 | 9 |
| Calcipotriene Ointment, 0.005% and Plaque Psoriasis | $12,450 | 0 | 1 |
| A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorPositive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | $8,426 | 1 | 2 |
Payments by Medical Specialty
Top Paid Doctors — Page 7
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Mariano Siragusa | Adult Health | Staten Island, NY | $241.80 | $0 |
| Richard Pidutti, Md, MD | Urology | Johnstown, PA | $241.30 | $0 |
| Mr. Mark Clarke, Npp32626, NPP32626 | Family | Smithfield, RI | $241.24 | $0 |
| James Bollinger, M.d, M.D | Urology | Paoli, PA | $241.11 | $0 |
| Daniel Voglewede, M.d, M.D | Urology | El Paso, TX | $241.08 | $0 |
| Dr. Shilpa Gupta, M.d, M.D | Pediatric Endocrinology | Riverside, CA | $240.44 | $0 |
| Nathaly Francois, M.d, M.D | Urology | Columbia, MD | $238.78 | $0 |
| Caleb Bozeman, M.d, M.D | Urology | Little Rock, AR | $238.67 | $0 |
| Dr. Justin Isariyawongse, M.d, M.D | Urology | Monroeville, PA | $238.11 | $0 |
| Royal Park, M.d, M.D | Urology | Torrance, CA | $237.78 | $0 |
| Huong Nguyen, M.d, M.D | Pediatric Endocrinology | Fresno, CA | $237.69 | $0 |
| Dr. David Cahn, Do, Mbs, Facos, DO, MBS, FACOS | Student in an Organized Health Care Education/Training Program | Media, PA | $237.43 | $0 |
| Padraic Mccahill, M.d, M.D | Urology | North Easton, MA | $237.15 | $0 |
| Victoria Shultz, Pa-C, PA-C | Physician Assistant | Springfield, OR | $236.94 | $0 |
| Sravan Panuganti, D.o, D.O | Urology | Gastonia, NC | $236.61 | $0 |
| Johnnie Lyles, M.d., M.b.a, M.D., M.B.A | Surgery | Charlotte, NC | $233.20 | $0 |
| York Moy, M.d, M.D | Urology | Middlebury, CT | $232.30 | $0 |
| Brittney Aupperle, Pa-C, PA-C | Physician Assistant | Latham, NY | $231.48 | $0 |
| Cindy Mesmer, Fnp, FNP | Family | Hyannis, MA | $231.19 | $0 |
| Dr. David Turk, Md, MD | Urology | Fort Wayne, IN | $230.95 | $0 |
| Dr. Zurab Davili, M.d, M.D | Surgery | Mayfield Hts, OH | $226.65 | $0 |
| John Buchanan, Fnp, FNP | Registered Nurse | Duluth, GA | $226.57 | $0 |
| Stanford Broder, Md, MD | Urology | Danbury, CT | $226.21 | $0 |
| Melissa Russell, M.d, M.D | Pediatric Endocrinology | Norfolk, VA | $224.79 | $0 |
| Mrs. Roberta Zbar, Arnp, ARNP | Primary Care | Boynton Beach, FL | $224.22 | $0 |
Ad
Top Products
- Leuprolide Acetate $1.7M
- Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064% $1.4M
Associated Products (13)
- Leuprolide Acetate $1.7M
- Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064% $1.4M
- JATENZO $1.2M
- TOL3010B $1.0M
- Paliperidone Palmitate $876,180
- TOL2707A $150,335
- TOL2581A $119,766
- Doxorubicin Hydrochloride Liposome Injection- Epithelial Ovarian Carcinoma $115,045
- TOL2708C $111,095
- Eligard 45mg and CPP $100,953
- TOL2649G $67,179
- Eligard $54,537
- Calcipotriene Ointment, 0.005% and Plaque Psoriasis $12,450
Payment Categories
- Food & Beverage $410,547
- Consulting $58,568
- Travel & Lodging $13,078
- Research $7.8M
About Tolmar, Inc.
Tolmar, Inc. has made $8.5M in payments to 9,082 healthcare providers, recorded across 24,484 transactions in the CMS Open Payments database. In 2024, the company paid $2.5M. The top product by payment volume is Leuprolide Acetate ($1.7M).
Payments were distributed across 146 medical specialties. The top specialty by payment amount is Hematology & Oncology ($209,143 to 153 doctors).
Payment categories include: Food & Beverage ($410,547), Consulting ($58,568), Research ($7.8M), Travel & Lodging ($13,078).
Tolmar, Inc. is associated with 13 products in the CMS Open Payments database, including Leuprolide Acetate, Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064%, and JATENZO.